Citadel Advisors
OREX

Citadel Advisors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Citadel Advisors’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-29,500
Closed -$38K – 9282
2017
Q4 		$38K Buy
29,500
+17,200
+140% +$28K ﹤0.01% 7714
2017
Q3 		$26K Buy
+12,300
New +$30K ﹤0.01% 7321
2017
Q2 		– Sell
-15,800
Closed -$54K – 8651
2017
Q1 		$54K Buy
+15,800
New +$62.4K ﹤0.01% 7029
2016
Q1 		– Sell
-1,790
Closed -$31K – 9285
2015
Q4 		$31K Sell
1,790
-50
-3% -$1.19K ﹤0.01% 7663
2015
Q3 		$39K Sell
1,840
-4,290
-70% -$147K ﹤0.01% 7764
2015
Q2 		$303K Buy
6,130
+290
+5% +$17.3K ﹤0.01% 5724
2015
Q1 		$457K Sell
5,840
-4,930
-46% -$306K ﹤0.01% 5039
2014
Q4 		$653K Buy
10,770
+6,630
+160% +$333K ﹤0.01% 4347
2014
Q3 		$176K Sell
4,140
-7,870
-66% -$423K ﹤0.01% 5859
2014
Q2 		$742K Buy
12,010
+5,860
+95% +$341K ﹤0.01% 3878
2014
Q1 		$400K Buy
6,150
+1,760
+40% +$119K ﹤0.01% 4667
2013
Q4 		$247K Sell
4,390
-2,810
-39% -$158K ﹤0.01% 4807
2013
Q3 		$442K Sell
7,200
-3,520
-33% -$238K ﹤0.01% 3937
2013
Q2 		$627K Buy
+10,720
New +$659K ﹤0.01% 3626

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's OREX Position: Q3 2017 in Review

Citadel Advisors sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2017, closing a stake of 20,920 shares — an estimated $51.1K sold.

Citadel Advisors first reported a position in OREX in Q2 2013 and held it in 14 quarters. The position peaked at $8.26M in Q3 2013. 42 funds tracked by Wall St. Rank hold OREX as of Q3 2017.

  • Citadel Advisors reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Citadel Advisors sold 20,920 Orexigen Therapeutics, Inc. shares in Q3 2017, an estimated $51.1K.
  • Citadel Advisors first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 14 quarters.
  • Citadel Advisors's Orexigen Therapeutics, Inc. position peaked at $8.26M in Q3 2013.
  • 42 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2017.

Based on Citadel Advisors's 13F filing for Q3 2017, filed 9 Nov 2017.